BioPharmX Corporation (NYSE:BPMX) enjoyed a 92.6% run-up in share price since hitting record low of $0.05. The stock managed -3.8% fall and now stands at $0.1 as of 3/8/2019. At a recent session, the prices were hovering between $0.095 and $0.105. This company shares are -100% up from its target price of $0 and the current market capitalization stands at $21.37M. The recent change has given its price a -10.51% deficit over SMA 50 and -72.87% deficit over its 52-week high. The stock witnessed -12.14% declines, -38.68% declines and -40.22% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BPMX’s volatility during a week at 9.77% and during a month it has been found around 7.55%.

BioPharmX Corporation (BPMX) Top Holders

Institutional investors currently hold around $3 million or 23.3% in BPMX stock. Look at its top three institutional owners: Vivo Capital, Llc owns $1.55 million in BioPharmX Corporation, which represents roughly 7.24% of the company’s market cap and approximately 51.6% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 6,328,195 shares of the stock are valued at $608 thousand. The third largest holder is Franklin Resources Inc, which currently holds $440 thousand worth of this stock and that ownership represents nearly 2.06% of its market capitalization.

BioPharmX Corporation 13F Filings

At the end of December reporting period, 7 institutional holders increased their position in BioPharmX Corporation (NYSE:BPMX) by some 2,487,576 shares, 14 decreased positions by 6,828,312 and 6 held positions by 20,248,824. That puts total institutional holdings at 29,564,712 shares, according to SEC filings. The stock grabbed 1 new institutional investments totaling 549,973 shares while 6 institutional investors sold out their entire positions totaling 1,085,252 shares.

BioPharmX Corporation (BPMX) Analyst Guide

Several analysts have released their opinion on BioPharmX Corporation (NYSE:BPMX), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].